Shopping Cart
- Remove All
Your shopping cart is currently empty
ELOVL1-IN-1 (1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide) is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $136 | In Stock | |
| 5 mg | $338 | In Stock | |
| 10 mg | $497 | In Stock | |
| 25 mg | $890 | In Stock | |
| 50 mg | $1,270 | In Stock | |
| 100 mg | $1,650 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $372 | In Stock |
| Description | ELOVL1-IN-1 (1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide) is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD). |
| In vitro | Administration of 1 nM-10 μM ELOVL1-IN-1 for 48 h reduces the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia[1]. |
| In vivo | Oral dministration of ELOVL1-IN-1 reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout mice (0.5-64 mg/kg; 28 days), wild‐type (WT) rats (30-300 mg/kg; 7 days), and cynomolgous monkeys (30 mg/kg; 7 days)[1]. |
| Synonyms | 1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide |
| Molecular Weight | 340.33 |
| Formula | C18H14F2N4O |
| Cas No. | 2227482-41-7 |
| Smiles | Fc1cc(ccn1)-n1ccc(NC(=O)C2(CC2)c2ccccc2F)n1 |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (146.92 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.88 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.